Some, such as semaglutide, have received FDA clearance to treat non-diabetic obesity and concomitant overweight
They can be viewed on a computer, tablet or mobile phone
In a retrospective cohort study of 16,827 patients in a single-center neuroophthalmology clinic, Hathaway et al found that semaglutide use was significantly associated with an increased incidence of NAION among patients with diabetes (HR = 4.28)
What is the pipeline for future medications for obesity
Whether you are just starting your first vial or transitioning between dose levels, every number you need is right here
An increase in IGF-1 in the circulation, in the liver and also in the muscle was observed in the Goat -/- mice, either as a result of the disordered GH pulse pattern, or because there was a failure of the elevated IGF-1 levels to feedback on GH release